Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.

Authors

Alexander I. Spira

Virginia Health Specialists, Fairfax, VA

Alexander I. Spira , Byoung Chul Cho , Tae Min Kim , Sang-We Kim , Bing Xia , Eunice Artis , Jessica Dobbs , Christine Baudelet , Mahadi Baig , Mehmet Ali Nahit Sendur

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).

First Author: Mariana da Rocha Almeida Brandao

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

First Author: Conor Ernst Steuer

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).

First Author: Rosario Garcia Campelo

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).

First Author: Qing Zhou